Is IRadimed Corp. overvalued or undervalued?

As of 31 October 2025, the valuation grade for IRadimed Corp. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 39, a Price to Book Value of 8.54, and an EV to EBITDA of 30.68. In comparison, peers such as Artivion, Inc. and BioLife Solutions, Inc. show significantly less favorable ratios, with negative P/E ratios and high EV to EBITDA values, suggesting that IRadimed Corp. is trading at a premium relative to its industry.
Despite the overvaluation, IRadimed Corp. has demonstrated strong performance with a year-to-date return of 39.65%, significantly outperforming the S&P 500's return of 16.30% over the same period. This performance, along with a high ROCE of 56.93% and ROE of 21.97%, reflects the company's operational efficiency, but the elevated valuation ratios indicate that the stock may not be a bargain at its current price of 76.81.